As of 14 Oct 2026, Neomorph has raised $100M across 1 verified round on record; latest: $100 million Series B led by Deerfield Management, announced 13 Apr 2026.
Neomorph develops molecular glue degraders to target and destroy disease-causing proteins.
2 sources
Sources agree. The San Diego dateline does not establish headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-13 | Deerfield Management | No recent discussion |
2 sources [ VERIFIED ] read against 2 sources Sources agree. The San Diego dateline does not establish headquarters. | ||||